{
  "scenario_id": "biotech_gene_editing_ethics_2025",
  "context": "Biotechnology firm developing CRISPR-based therapies for rare genetic disorders, evaluating ethical implications of germline editing for hereditary disease prevention",
  "stakeholders": {
    "requester": "Chief Scientific Officer",
    "approvers": [
      "CEO",
      "Board of Directors",
      "Ethics Review Board"
    ],
    "influencers": [
      "Patient Advocacy Organizations",
      "Regulatory Authorities",
      "Bioethics Experts",
      "Scientific Community"
    ]
  },
  "request": {
    "amount": "$75 million",
    "purpose": "Initiate clinical development program for germline gene editing therapy targeting hereditary diseases",
    "urgency": "critical",
    "justification": "Potential to prevent transmission of devastating genetic diseases to future generations, addressing unmet medical need"
  },
  "decision_process": [
    {
      "stage": "ethical_assessment",
      "duration": "6 weeks",
      "activities": [
        "International bioethics consultation",
        "Public engagement forums",
        "Risk-benefit analysis framework development"
      ],
      "outcome": "Ethical framework established with strict inclusion criteria and long-term monitoring requirements"
    },
    {
      "stage": "scientific_peer_review",
      "duration": "8 weeks",
      "activities": [
        "Independent scientific validation",
        "Off-target effect assessment",
        "Long-term safety modeling"
      ],
      "outcome": "Scientific validity confirmed with acceptable safety profile for controlled clinical investigation"
    },
    {
      "stage": "regulatory_strategy",
      "duration": "10 weeks",
      "activities": [
        "Global regulatory agency consultations",
        "Adaptive regulatory pathway development",
        "International harmonization efforts"
      ],
      "outcome": "Regulatory strategy developed with conditional approval pathways and enhanced monitoring requirements"
    },
    {
      "stage": "stakeholder_alignment",
      "duration": "4 weeks",
      "activities": [
        "Patient community engagement",
        "Healthcare provider consultations",
        "Public communication strategy"
      ],
      "outcome": "Broad stakeholder support secured with transparent communication and engagement commitments"
    }
  ],
  "business_impact": {
    "expected_market_size": "$5 billion",
    "projected_revenue": "$3.2 billion",
    "risk_factors": [
      "Ethical controversy leading to public backlash",
      "Regulatory uncertainty and potential bans",
      "Technical challenges in germline editing precision",
      "Long development timelines and high costs"
    ]
  }
}
